Codexis shares tumble as Q4 results miss estimates, outlook disappoints

Published 27/02/2025, 22:46
Codexis shares tumble as Q4 results miss estimates, outlook disappoints

REDWOOD CITY, Calif. - Codexis , Inc. (NASDAQ:CDXS) shares plunged 10.4% after the enzymatic solutions provider reported fourth-quarter results that fell short of analyst expectations and provided a tepid outlook for 2025.

The company posted a loss of -$0.13 per share for Q4, significantly wider than the -$0.04 loss analysts had forecast. Revenue came in at $21.5 million, well below the consensus estimate of $28.2 million and down 19.2% YoY when including 2023 PAXLOVID-related enzyme sales.

For the full year 2024, Codexis reported total revenue of $59.3 million, a 4% decrease from 2023 excluding PAXLOVID sales. The company’s product revenue increased 6% to $36.8 million, while R&D revenue declined to $22.6 million from $27.2 million in 2023.

Looking ahead, Codexis provided 2025 revenue guidance of $64-68 million, the midpoint of which is roughly in line with analyst expectations of $66.6 million. The company expects to achieve double-digit revenue growth in 2025 as it accelerates commercial growth through its double-stranded RNA ligase and GLP-grade siRNA material offerings.

"Throughout 2024, we continued to execute our strategy to advance the ECO Synthesis™ platform," said Stephen Dilly, Chairman and CEO of Codexis. "As we look to the year ahead, we will be focused on delivering a wide array of services to siRNA innovators."

The company aims to sign its first development contract for ECO Synthesis™ manufacturing services in the first half of 2025 and secure a GMP scale-up partner by year-end to enable larger scale clinical and commercial siRNA production.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.